STRN3 and cancer: Previously, we showed that peptide mimetics-mediated selective targeting of the STRN3-containing PP2A can restore the Hippo signaling against cancer and that targeting STRIPAK complex can inhibit DNA repair therefore sensitizing cancer to PARP inhibition (16, 26).